PTPI Stock Earnings: Petros Pharmaceuticals Misses EPS, Misses Revenue for Q4 2023InvestorPlace • about 1 month ago
InvestorPlace - Stock Market News, Stock Advice & Trading Tips
PTPI stock results show that Petros Pharmaceuticals missed analyst estimates for earnings per share and missed on revenue for the fourth...
Share to Feed
Nitrate patients subgroup demonstrated 100% correct self-selection when utilizing the web app technology with the drug facts label compared to 40% when using drug facts label alone (among 86% vs. 56...
Liberty Health Sciences (OTCMKTS:LHSIF - Get Free Report) and Petros Pharmaceuticals (NASDAQ:PTPI - Get Free Report) are both small-cap medical companies, but which is the better stock? We will...
Petros begins enrollment in AI integrated Human Factors Study to optimize self-screening, continuing its efforts to make STENDRA (avanafil) the first erectile dysfunction medication to achieve OTC...
See the rest of the story here.
thefly.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fly's real-time, streaming news feed keeps individual...
AI software expected to further enable Petros's efforts to make STENDRA the first ED product to be offered over the counterNEW YORK, NY / ACCESSWIRE / February 14, 2024 / Petros Pharmaceuticals, Inc...
FDA requests meeting to review the Company's technology component and discuss further development and requirementsNEW YORK, NY / ACCESSWIRE / January 24, 2024 / Petros Pharmaceuticals, Inc...
There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Petros Pharmaceuticals (PTPI Research Report), Ath...
Over 78% of technology-enabled subjects correctly self-selected vs. 56% using drug facts label alone demonstrating continued progress toward STENDRA(R) working to become the first erectile...